Orthofix and CGBio partnered for the development and commercialization of Novosis, a bone growth material and regenerative products.

AlloSource's president and CEO, Tom Cycyota, plans to retire after leading the biologics company for 22 years.

Anika Therapeutics earned the American Orthopedic Society for Sports Medicine's ACE award for cutting-edge innovation for its Tactoset product.

Five orthopedic surgeons are part of a new regenerative medicine scientific advisory board for Mimedx.

Orthofix's Virtuos Lyograft allograft was debuted by neurosurgeon Thomas Ellis, MD.

NovaBone, a biologic medtech company focused on orthopedic and dental products, hired Brian Carlisle as CEO.

From a notable stem cell study to newly launched products, here are eight updates in regenerative orthopedic medicine:

Ossifix Orthopedics will launch its demineralized bone matrix, made from 100 percent human bone tissue in August.

The Pediatric Orthopedic Center in Cedar Knolls, N.J., became the first pediatric-only orthopedic practice in its region to add the Bear implant for ACL restoration.

Scientists in the U.K. have found that a new drug being tested for cancer therapy may also be able to reduce damage in patients with spinal cord injuries.

Spiderwort, a startup developing cellulose-based tissue scaffolding to treat acute spinal cord injuries, has secured $13.2 million through a series A financing round, the company said July 12.

Regenerative medicine in orthopedics has developed in the first half of 2022, and many surgeons have a positive outlook toward it.

AlloSource added the AlloFuse microfibers demineralized bone allograft to its product line.

Istos Biologics launched the Influx Fibrant line of 100 percent cortical allograft products.

Aziyo Biologics co-founder Randal Mills, PhD, was named interim president and CEO.

Theradaptive's OsteoAdapt SP implant received its third FDA breakthrough designation.

A Cincinnati pain management physician led the first prospective controlled trial in the world on treating chronic back pain with stem cells, with about 70 percent of participants seeing positive results.

Royal Biologics received FDA approval for its MAXX-BMC bone marrow aspirate concentration system.

Although further research is needed to determine the safety and efficacy of regenerative procedures in the spine, the potential of many of these therapies — such as stem cells, platelet-rich plasma and bone marrow aspirate — is considerable.

From patent updates to grants, here are five developments in orthopedic biologics over the last 30 days: